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Tumor regression grading of gastrointestinal carcinomas
after neoadjuvant treatment
 
Multimodal therapy concepts have been successfully implemented in the treatment of
 
locally advanced gastrointestinal malignancies. The effects of neoadjuvant chemo- or
 
radiochemotherapy such as scarry fibrosis or resorptive changes and inflammation can  
be determined by histopathological investigation of the subsequent resection specimen.  
Tumor regression grading (TRG) systems which aim to categorize the amount of regressive  
changes after cytotoxic treatment mostly refer onto the amount of therapy induced fibrosis  
in relation to residual tumor or the estimated percentage of residual tumor in relation to the  
previous tumor site. Commonly used TRGs for upper gastrointestinal carcinomas are the  
Mandard grading and the Becker grading system, e.g., and for rectal cancer the Dworak or  
the Rödel grading system, or other systems which follow similar definitions. Namely for  
gastro-esophageal carcinomas theseTRGs provide important prognostic information since  
complete or subtotal tumor regression has shown to be associated with better patient’s  
outcome. The prognostic value of TRG may even exceed those of currently used stag-  
ing systems (e.g., TNM staging) for tumors treated by neoadjuvant therapy. There have  
been some limitations described regarding interobserver variability especially in borderline  
cases, which may be improved by standardization of work up of resection specimen and  
better training of histopathologic determination of regressive changes. It is highly recom-  
mended thatTRG should be implemented in every histopathological report of neoadjuvant  
treated gastrointestinal carcinomas. The aim of this review is to disclose the relevance of  
histomorphologicalTRG to accomplish an optimal therapy for patients with gastrointestinal  
carcinomas.  
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INTRODUCTION
Multimodal treatment has been successfully introduced in the
therapy of gastrointestinal malignancies. Preoperative chemo- or
radiochemotherapy followed by surgery or perioperative treat-
ment currently represents the standard approach for locally
advanced esophageal, gastric, and rectal carcinomas, providing
survival benefit for the patients compared to surgery alone, and
especially patients with complete or subtotal regression of the
tumors show significant improved survival rates (1–9).
The effects of neoadjuvant chemo- or radiochemotherapy can
be determined by histopathological investigation of the subse-
quent resection specimens (10–13). Not all tumors show regressive
changes in a similar manner. In most cases, complete or subtotal
tumor regression after neoadjuvant treatment is associated with
better outcome of the patients. There exist many tumor regres-
sion grading (TRG) systems which aim to categorize the amount
of regressive changes after cytotoxic treatment – mostly they refer
to the amount of therapy induced fibrosis in relation to resid-
ual tumor (14, 15) or the estimated percentage of residual tumor
in relation to the previous tumor site (12, 16–19). Since they
have been shown to provide highly valuable prognostic informa-
tion they may represent a morphological marker for subsequent
guiding of patients after neoadjuvant treatment and surgery.
In this review we will present examples of four very com-
monly used TRG systems for gastrointestinal carcinomas, discuss
their clinical and prognostic relevance and also address the lim-
itations and critical issues such as interobserver variability and
lack of standardization, finally presenting a personal proposal for
an instruction of a standardized macroscopic and histologic work
up of resection specimens of neoadjuvant treated gastrointestinal
carcinomas.
REGRESSIVE ALTERATIONS OF THE TUMORS AFTER
NEOADJUVANT THERAPY
In many cases the pathologist can already roughly estimate the
degree of tumor regression by macroscopy (Figure 1). The histo-
logic appearance of regression of these tumors (Figure 2) basically
represents a subacute-subchronic inflammation because most
tumors are resected after a delay of several weeks after completion
of the preoperative treatment.
Significant regressive changes may result in complete disap-
pearance of malignant cells and replacement of the tumor by
fibrous or fibro-inflammatory granulation tissue. Signs of resorp-
tion, like histiocytic reaction with hemosiderin-laden and foamy
macrophages, cholesterol deposits, and foreign body reaction, as
well as dystrophic calcifications can be seen (10–12, 20). In this
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FIGURE 1 | Gross images of esophageal adenocarcinomas with
(A) macroscopic significant regression and (B) no macroscopic
significant regression after neoadjuvant chemotherapy.
context it should be stressed, that especially the presence of foamy
histiocytes has been shown to be most specific for regression due
to previous cytotoxic treatment while stromal changes like fibrosis,
granulating inflammation following endogenous tumor necrosis
can also be observed in untreated carcinomas (12). Another fre-
quent finding of adenocarcinomas treated by neoadjuvant therapy
is the presence of acellular mucin lakes (12, 21, 22). They should
not be considered as viable residual tumor, however the presence
of mucin lakes warrants an intense search for residual vital tumor
cells (10). Tumor regression may also follow a centrifugal pattern,
and even if the superficial tumor has completely regressed, resid-
ual tumor may be found in deeper areas of the tumor bed or at the
periphery, respectively (12).
On the cellular level, the residual malignant cells can show
eosinophilic cytoplasm, vacuolization of cytoplasm, or undergo
oncocytic differentiation. Development of neuroendocrine differ-
entiation may be seen. Marked nuclear atypia with hyperchroma-
sia, karyorrhexis, pyknosis, or enlargement of nuclei with some-
times bizarre formations are frequent findings. Giant cells may
also be present. Mitoses are found rarely in contrast to apoptotic
figures. These alterations may be quite localized, with histolog-
ically typical areas of cancer infiltrates immediately adjacent to
marked cytopathic atypical cells (10, 12, 20).
Bizarre stromal fibroblasts can be observed in tumoral and
non-tumoral tissue. Vascular alterations like myxohyaline inti-
mal proliferation of vessels, sometimes with highly atypical
endothelial cells, telangiectasia, organizing thrombi, and endar-
teritis obliterans are frequently seen. The non-neoplastic tis-
sue may also undergo treatment associated changes, such as
non-tumorous inflammatory ulceration, submucosal edema,
and inflammation. Epithelial changes comprise variabilities in
nuclear/cytoplasmic ratio, nuclear pleomorphism, condensed
chromatin, and the presence of prominent, multiple, and irreg-
ular nucleoli. Gland structures of the esophagus and stom-
ach may show atrophy and metaplastic changes (10, 12, 20).
All these findings on non-neoplastic tissue may sometimes
appear worrisome and can be difficult to distinguish from
cancer.
FIGURE 2 | Histologic findings of tumors treated by neoadjuvant
(radio) chemotherapy. (A) Fibrosis replacing previous large parts of the
tumor which is evident only by scattered residual tumor glands
(Hematoxylin and Eosin (HE) stain, 10×); (B) Acute necrosis (HE stain, 10×);
(C) Acellular mucin lakes (HE, 20×); (D) Foamy histiocytes and resorptive
changes with cholesterol clefts and chronic inflammation (HE, 20×);
(E) Regressive tumor gland adjacent to a better preserved viable gland (HE,
25×); (F) High grade cellular atypia in regressive tumor glands. Note the
intratubular histiocytes as sign of resorption (HE, 40×).
CLASSIFICATION OF TUMOR REGRESSION
Tumor regression grading systems aim to categorize the amount
of regressive changes after cytotoxic treatment in order to demon-
strate potential prognostic information based on objectively
determinable histopathologic findings. As stated above, many
histopathologically detectable alterations and findings are only
infrequently seen and not entirely specific for tumor regression
after cytotoxic treatments. Therefore the regression grading sys-
tems refer mostly onto single, better reproducible parameters, such
as the amount of therapy induced fibrosis in relation to residual
tumor or an estimated percentage of residual tumor in relation
to the previous tumor site. The TRG systems according to Man-
dard (15), Becker (12), Dworak (14), or Rödel (17) are examples
for commonly used TRGs, which represent different approaches
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for estimating the degree of tumor regression. An overview about
the various TRGs is given in Table 1.
TRG ACCORDING TO MANDARD
The Mandard classification system was published in 1994 and first
applied for estimation of tumor regression in squamous cell carci-
nomas of the esophagus after neoadjuvant treatment with cisplatin
and radiotherapy (15). In this study 93 resected specimens were
examined. First, the macroscopic impression was divided into
three macroscopic groups: obvious residual tumor with ulcera-
tion/fungating/infiltrative feature, apparent tumor regression and
scarring, and the last group included doubtful cases. On histology
the specimens were separated into two groups with or without
regressive changes, while the regressive changes included the stro-
mal changes and cytological alterations. Basing on these changes
the tumor regression was classified into five histological TRGs
(Table 1), based on vital tumor tissue at the ratio of fibrosis:
TRG 1 was defined as complete regression (=fibrosis without
detectable tissue of tumor); TRG 2 was defined as fibrosis with
scattered tumor cells; TRG 3 was fibrosis and tumor cells with pre-
ponderance of fibrosis; TRG 4 was fibrosis and tumor cells with
preponderance of tumor cells; TRG 5 was tissue of tumor without
changes of regression. Forty-two percent of the tumors were TRG
1–2, 20% were TRG 3, and 33% were TRG 4–5. A high correlation
of the disease-free survival (DFS) with the TRG, tumor size, lymph
node status, and esophageal wall involvement was seen in univari-
ate analysis. In multivariate analysis, only tumor regression (TRG
1–3 vs. TRG 4–5) remained significant predicator of DFS. In the
following years this TRG system was widely applied on each kind
of gastrointestinal cancers after neoadjuvant treatment rendering
it one of the most widely used TRGs (10).
TRG ACCORDING TO BECKER
In 2003, Becker et al. (12) proposed a different grading system
for advanced gastric carcinomas treated by cisplatin based neoad-
juvant chemotherapy. In this study, 36 patients with gastric car-
cinoma were treated neoadjuvant with combined chemotherapy
(etoposide, doxorubicin, and cisplatin). The entire macroscopi-
cally identifiable residual tumor areas of the specimens and the
scarring area were investigated histologically and compared with
specimens treated only with surgery alone. The grading of the
tumor regression was based on the estimation of the percentage
of vital tumor tissue in relationship to the macroscopically iden-
tifiable tumor bed (previous site of the tumor) and divided into
three grades (Table 1). TRG 1a was defined as complete tumor
regression without residual tumor; TRG 1b was defined as <10%
residual tumor per tumor bed, like a subtotal tumor regression.
TGR 2 illustrated a partial tumor regression with 10–50% residual
tumor and at the findings of >50% residual tumor cells with or
without signs of treatment effect the tumor regression was classi-
fied as TRG 3 (Figure 3). In this study none of the 36 patients had
complete tumor regression, 4 patients had TRG 1b, 9 patients had
TRG 2 and 23 patients had TRG 3 with more than 50% vital tumor
cells. Similar to Mandard, the TRG correlated significantly with
survival, besides tumor size and lymphatic vessel invasion. After
its description the Becker system was successfully applied in other
gastrointestinal malignancies (23, 24). In 2011 the same group
confirmed the findings of the initial study by analyzing 480 gastric
carcinomas rendering TRG as independent prognostic factor for
gastric cancer besides postoperative lymph node status (25).
A large number of other regression grading systems use the
principle of the estimation of residual tumor for classification
of TRGs: the Japanese Society for Esophageal Disease designate
tumor regression as a continuous variable and categorized into
four groups as a measure of the extent of chemoradiation response:
ypV0, no viable cell; ypV1, 1–33% viable tumor; ypV2, 34–66%
viable tumor; and ypV3, 67–100% viable tumor (26). The regres-
sion grading to Schneider for esophageal cancer is a four step-
grading system basing on the percentage of vital tumor cells using
the same cut-offs like the Becker system (16). The British Royal
College of Pathologists describes a modified grading system with
the following cut-offs: 0–5, 5–50 and >50% residual tumor (27).
TRG ACCORDING TO DWORAK
For rectal cancer, in 1997 the group of Dworak et al. (14) described
their TRG system basing on the findings on 17 patients who
had received preoperative radiochemotherapy with 5-FU/50 Gy.
According to the macroscopic features different techniques of
sampling of the tumor tissue were applied. If no visible tumor
tissue was present the whole suspect area of fibrosis was sliced
Table 1 | Examples for tumor regression grading systems.
Mandard et al. (15) Becker et al. (12) Dworak et al. (14) Rödel et al. (17)
1. Complete regression (= fibrosis
without detectable tissue of tumor)
1a. No residual tumor/tumor
bed+ chemotherapy effect
0. No regression 0. No regression
2. Fibrosis with scattered tumor
cells
1b. <10% Residual tumor/tumor
bed+ chemotherapy effect
1. Predominantly tumor with significant fibrosis
and/or vasculopathy
1. Regression of <25%
of tumor mass
3. Fibrosis and tumor cells with
preponderance of fibrosis
2. 10–50% Residual tumor/tumor
bed+ chemotherapy effect
2. Predominantly fibrosis with scattered tumor
cells (slightly recognizable histologically)
2. Regression of
25–50% tumor mass
4. Fibrosis and tumor cells with
preponderance of tumor cells
3. >50% Residual tumor/tumor
bed± chemotherapy effect
3. Only scattered tumor cells in the space of
fibrosis with/without acellular mucin
3. Regression of >50%
tumor mass
5. Tissue of tumor without changes
of regression
4. No vital tumor cells detectable 4. Complete regression
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FIGURE 3 | Examples of tumor regression grades according to Becker.
(A) TRG 1a complete regression. This image would be classified as TRG 1
according to Mandard and TRG 4 according to Dworak. (B) TRG 1b <10%
residual tumor. Mandard TRG would be 2, Dworak TRG 3. (C) TRG 2
10–50% residual tumor. Mandard TRG would be 3, but 2 could also be
possible since there is no strict definition of “scattered tumor cells” and
“preponderance of fibrosis”; Dworak TRG would be 2: the term “scattered
tumor cells” is by complemented by “histologically slightly recognizable.”
(D) TRG 3 >50% residual tumor. Mandard TRG would be 4 or 5 and Dworak
0 or 1 since one can appreciate fibrotic stands which could be preexisting
desmoplasia or regression.
and embedded. For macroscopically obvious tumor, a minimum
of four paraffin blocks was processed and an additional large area
block was embedded. The grading of regression was established as
follows (Table 1): TRG 0 tumor without regression, TRG 1 with
dominant tumor mass with obvious fibrosis and/or vasculopathy.
TRG 2 shows dominantly fibrotic changes with few tumor cells or
groups, easy to find, while TRG 3 describes only very few tumor
cells, difficult to find, in the fibrotic tissue with/without mucous
substance. For TRG 4 only fibrotic mass without tumor cells exist,
i.e., total regression or response. Although based on a very small
sample size, the Dworak system is now widely applied on rectal
cancer and also recommended by several national guidelines (28).
TRG ACCORDING TO RÖDEL
In 2005, Rödel et al. (17) have used a five tiered score for the esti-
mation of tumor regression in rectal cancer ranging from grade
0 (no regression) to grade 4 (complete regression) in <25, 25–50,
and >50% intervals which do not describe the amount of resid-
ual tumor but the degree of tumor regression (Table 1). In their
study, complete regression was observed in 10% of the cases and
an intermediate pathologic response (TRG 2 and 3) could be
detected in 65%. Complete and intermediate pathologic response
suggested improved DFS after preoperative radiochemotherapy
and surgery. For esophageal cancer, Rizk et al. have been using
a similar approach by estimation the degree of tumor regression
instead of residual tumor. They defined six grades (0–20% regres-
sion; 20–50% regression; 50–80% regression; 80–90% regression;
90–99% regression; 100% regression) (19).
PROGNOSTIC SIGNIFICANCE OF TRG
There are numerous studies which show the prognostic relevance
of TRGs. For upper gastrointestinal cancers there is the strongest
evidence for the association between TRG and patient outcome.
There is the general observation that patients with complete tumor
regression do best (10, 25). For esophageal squamous cell and
adenocarcinomas some studies could also demonstrate a bene-
fit for patients with subtotal and partial tumor regression (i.e.,
Becker 1b and 2; Mandard 2 and 3), supporting a distinct biology
of esophageal carcinomas (6, 11). For gastric cancer, in contrast,
there seems to be a clear discrimination into responding patients
with complete and subtotal regression (i.e., Becker 1a, b; Man-
dard 1 and 2) and non-responders with partial and no regression
(i.e., Becker 2 and 3; Mandard 3–5) (25). Interestingly an associa-
tion between tumor localization and tumor type and TRG could
be shown, more distal cancers of Laurens diffuse type having the
lowest probability for showing significant tumor regression after
neoadjuvant chemotherapy (29).
For rectal cancer, two works have also provided convincing
evidence to support TRG as an independent predictor of sur-
vival (7–9). Patients with pathological complete regression showed
improved disease-free survival, lower risk of local recurrence, bet-
ter chance of being free from distant metastasis and increased
overall survival. TRG, especially in terms of complete regression,
therefore is considered to representing a potential tool to guide
therapy in patients with rectal cancer as well (30). Additionally, in
a very recent meta-analysis, partial tumor regression was described
as being associated with improvement in DFS and was therefore
also considered as favorable prognostic factor (31).
The prognostic value of TRG may even exceed those of cur-
rently used staging systems (e.g., TNM staging) which are origi-
nated from data from untreated tumors. The AJCC (32) but not
the UICC (33) considers TRG as additional prognostic factor for
rectal carcinomas after preoperative treatment, but do not inte-
grate this into a defined staging system. Therefore, several authors
have proposed alternative staging systems incorporating tumor
regression grades for carcinomas treated by neoadjuvant ther-
apy in order to provide better prognostication for the patients
who had undergone preoperative treatment before surgery (16,
18, 34). However, although promising, these proposed prognostic
classifications have not entered clinical practice yet.
CRITICAL ISSUES OF TRG
The most critical issues regarding the histopathologic estimation
of a tumor regression grade are inter- and intra-observer vari-
ability and the lack of standardization. These two factors may
be the reason for sometimes marked differences in reporting the
prognostic value of TRGs which is evident especially for rectal
cancers.
Recently, Chetty et al. (35) investigated the level of concordance
among expert gastrointestinal pathologists for regression grading
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in rectal cancer treated with neoadjuvant chemoradiation. In this
study seventeen pathologists applied the Mandard, the Dworak,
and the modified Royal College of Pathologists (mRCP) regression
grading systems on selected slides of 10 tumors. Only in one of
ten cases did all 17 participants agree concordantly. The Mandard
and Dworak grading systems had unsatisfactory interobserver-
agreement with kappa values of 0.28 and 0.35, respectively. The
mRCP system which bases on the estimation of residual tumor
in percentage showed slightly better kappa values with overall
kappa-score of 0.38. The study also contained a questionnaire
for the contributing pathologists covering several aspects of TRG.
The paper concluded that there was a need for a simple, repro-
ducible regression grading system with clear criteria. Moreover,
the authors recommended a cumulative or composite score tak-
ing into account all sections of the tumor bed that is sampled
rather than the worst section and finally a uniform method of
sampling of these specimens. Other studies, in contrast, demon-
strate a good reproducibility of TRGs; however, they show that
the most frequent source of disagreement was assessment of the
relative amount of fibrosis, while displacement of epithelium or
the misinterpretation of acellular mucin was a minor source of
disagreement (36–38).
A very recent study by Mirza et al. (39) compared three TRG
systems (Mandard, Japanese Society for Esophageal Disease and
Becker) based on their reproducibility and ability to predict sur-
vival for gastric carcinomas and adenocarcinomas of the gastro-
esophageal junction after neoadjuvant chemotherapy. Sixty-six
cases were reviewed by two histopathologists. The highest kappa-
score was achieved for the grading system described by Becker
(kappa-score= 0.52). The Mandard grading system achieved a
kappa-score of 0.44, while the Japanese Grading system had the
lowest score with 0.28. While both Mandard and Becker TRGs were
associated with patient prognosis, the Becker system was the most
reproducible system, and the usage of the percentage of viable
tumor cells as criterion of response appeared to be more easily
and reproducibly identifiable than the use of the degree of fibrosis.
Similar results with respect to the reproducibility of TRG assess-
ment using percentage of residual tumor have also been presented
in a study of Wu et al (36).
STANDARDIZATION OF WORK UP AND REPORTING TRG
Currently there are only few published recommendations for han-
dling of surgical resection specimens although recent papers have
demonstrated the strong demand for the implementation of stan-
dardization in this field (30, 40). Some authors consider standard
processing protocols used for routine cases as appropriate if tumor
is grossly visible (10). However, there is general agreement if
viable tumor is not grossly evident, embedding the whole sus-
picious area with the application of step sectioning should be
performed (10). For the reliable assessment of complete tumor
regression in rectal cancer for example, the second European Rec-
tal Cancer Consensus Conference recommended to take initially
at least five tissue blocks from the tumor site, and the whole tumor
area should be blocked only if there is no viable tumor. They
consider the diagnosis of complete pathological response as appro-
priate if after additional three levels step sections still no tumor is
present (41).
The authors of the present paper would recommend the
embedding of the entire tumor bed from the beginning. Small
residual tumor infiltrates in the periphery, which is a frequent find-
ing, cannot be detected when the tumor bed is not entirely blocked
for histopathological analysis. In cases where the tumor bed mea-
sures more than 8 cm in largest dimension, significant regression is
unlikely and taking blocks following the longitudinal and vertical
largest dimension can be considered as sufficient. If then no or less
residual tumor is detected, complete embedding of the remaining
tumor bed can be performed in a second step. Moreover, following
own experience and supported by the findings of others (36, 39)
the authors favor the four tiered Becker system basing on percent-
age of residual tumor over TRGs which base on the estimation of
fibrosis in relation to residual tumor. A personal proposal for a
standardized grossing and histopathological reporting is provided
in Table 2.
CONCLUSION
In summary, assessing tumor response to neoadjuvant treatment
has been shown to be feasible by histopathological examination
of the resected specimens in gastrointestinal carcinomas. There-
fore, it is highly recommended that TRG should be implemented
in every histopathological report of neoadjuvant treated gastroin-
testinal carcinomas. As mentioned above, e.g., the Mandard or the
Table 2 | Personal proposal for standardized work up and reporting of
TRG [modified from Ref. (11)].
PHOTOGRAPHIC DOCUMENTATION
Photocopy or photograph of resection specimen (orientation and
documentation of blocks and of histologically proven residual tumor)
Macroscopic description; tumor size (three-dimensional), distance to
resection margins
WORK UP
Inking of the deep (circumferential) resection margin
Complete embedding of the macroscopically identifiable tumor bed,
orientated from proximal to distal in 0.5 cm levels. If tumor bed >8 cm,
significant regression in unlikely: first take blocks following the
longitudinal and vertical largest dimension. If no or less residual tumor
embed remaining tumor bed in second step. CRM is included in these
blocks
All slides stained by Hematoxylin/eosin, selected blocks by periodic
acid-schiff, Elastica van Gieson staining; immunohistochemistry may be
helpful for discrimination of histiocytes and alterated tumor cells
If no residual tumor: another three step sections to confirm complete
response
Resection margins oral, aboral
Additional macroscopic findings
Lymph node stations. Immunohistochemistry (pan-cytokeratin) if ypN0
PATHOLOGICAL REPORT SHOULD INCLUDE
UICC ypTNM status (including L, V, Pn)
UICC R-status
Distance to circumferential resection margin (esophagus; rectum)
Grading, typing (according to WHO; additionally Lauren’s type for upper
GI adenocarinomas)
Histopathological tumor regression grade (e.g., Becker TRG 1a, 1b, 2, 3)
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Becker systems have been successfully applied on tumors different
from the site of original description. However, an internation-
ally accepted robust system for the grading of tumor regression
in gastrointestinal malignancies following neoadjuvant chemora-
diotherapy is still required. Currently existing weaknesses such
as interobserver variability may be reduced by individual and
institutional training (e.g., participation on ring trials). Both the
pathologists’ and clinicians’ community have to work on stan-
dardization of specimen processing and reporting of TRGs. With
regard to the various TRG systems, it may be a major challenge
for an international and interdisciplinary commission to find a
consensus on TRG reporting. For the future, however, this may be
the prerequisite for generating reliable, evidence based data regard-
ing the prognostic impact of TRG finally rendering it as powerful
prognostic morphologic biomarker which then also should be
integrated part of clinical staging systems. This may help with clin-
ical decision-making, influence surgical strategies, postoperative
adjuvant therapy, and surveillance intensity.
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